Business Context and Reporting Period
This Form 8-K filing by Eton Pharmaceuticals, Inc. (Delaware) reports events occurring on November 15, 2018, with the report dated November 20, 2018. The filing documents corporate governance amendments executed in connection with the closing of the Company's initial public offering (IPO).
Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on legal and structural changes to the Company's charter.
Material Changes
The primary material change is the amendment and restatement of the Company's Certificate of Incorporation and Bylaws effective upon the IPO closing. Key structural changes include:
- Capital Structure: Authorization of 50,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.
- Preferred Stock: Elimination of all references to previously existing series of preferred stock.
- Board Composition: Implementation of a classified board with three classes of directors serving staggered three-year terms.
- Director Removal: Directors may only be removed for cause, requiring an affirmative vote of at least two-thirds of the voting power of outstanding shares.
- Shareholder Actions: Elimination of the ability for stockholders to take action by written consent in lieu of a meeting.
- Special Meetings: Authority to call special meetings is restricted to the Board, the Chairman, the CEO, or holders of at least 40% of the voting power.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management outlook, or discussion of operational risks. The document serves as a notice of the effective date of the new governance documents and references the full text of the Amended Certificate and Bylaws filed as Exhibits 3.1 and 3.2.
Key Facts for Investor Verification
- Confirm the exact number of shares issued and outstanding following the IPO closing.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for specific anti-takeover provisions.
- Verify the composition of the initial Board of Directors under the new staggered term structure.
- Check subsequent filings for the issuance of any new series of preferred stock from the authorized 10,000,000 shares.